Abstract 69P
Background
Cripto-1 (CR1) is an oncofetal protein required for implantation and expressed in the adult during wound repair, inflammation, and tumorigenesis. A second gene codes for a very homologous protein, Cripto-3 (CR3). Both proteins contain 188 amino acids and differ only in 6 residues. Heretofore, all available antibodies cannot discriminate between these two proteins, preventing any investigation on their differential contributions to cancer biology. Here, we present the generation, characterization, and clinical implications of highly specific monoclonal antibodies (MoAbs) for these two proteins.
Methods
Different peptide fragments of either protein were used as antigens to generate mouse MoAbs (233 clones for CR1, 319 clones for CR3) that were selected by their target protein specificity through SPR and ELISA assays. Selected MoAbs were used for immunohistochemistry on tissue arrays including normal tissues as well as cancers of the lung, breast, colon, ovary, and prostate. MoAbs were also used for Western blotting and ELISA characterization of human serum (breast cancer vs healthy controls).
Results
MoAbs NCI 5G1-1 and NCI 5G11-2 were highly specific for CR1 and CR3, respectively. No crossreactivity was observed with the other protein. Immunohistochemical analysis of cancer specimens showed differential staining patterns, where some tumor cells expressed both proteins, others expressed only CR3, and still others show vascular endothelial cells stained for CR1 while tumor cells express CR3. In prostate, colon, and breast cancer, CR1 and/or CR3 protein expression correlates with clinical parameters, such as TMN_N, TMN_M, tumor stage, tumor grade, or PR expression. Lastly, both CR1 and CR3 interact with established binding proteins Nodal, GRP78 and Alk4 and competitively interfere with one another for targeted binding.
Conclusions
We describe for the first time the development of MoAbs that discriminate human CR1 from CR3, confirming that CR3 is translated into a protein in human cells, thus removing its pseudogene status. We also confirm CR1, and propose CR3, as cancer prognosis and severity markers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain.
Funding
Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
56P - SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume
Presenter: Christa Dijkhuizen
Session: Poster session 09
57P - Metastasis organotropism: Unveiling associated proteins using network biology
Presenter: Margarida Carrolo
Session: Poster session 09
59P - Correlation of tumor microenvironment signature in advanced stage non-small cell lung cancer with EGFR mutation who received EGFR-TKIs
Presenter: Chaiyapong Ngamchokwathana
Session: Poster session 09
60P - Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation
Presenter: Xuejin Ou
Session: Poster session 09
61P - Next generation sequencing and its clinical utility in advanced cancer: Single institute experience from low-middle income country
Presenter: Amit Badola
Session: Poster session 09
62P - Prebiotics modulate gut microbiota-mediated T cell immunity to enhance sintilimab inhibition of lung cancer
Presenter: QIN YAN
Session: Poster session 09
63P - Addition of human chorionic gonadotropin to the current standard mobilization approach with granulocyte-colony stimulating factor increases overall survival in a murine model of peripheral blood stem cell transplantation: Are we far enough for therapy?
Presenter: Andrei Cismaru
Session: Poster session 09
64P - Developing novel therapeutics for bladder cancer leveraging drosophila models
Presenter: Takuya Moriguchi
Session: Poster session 09
65P - Ionizing radiation induces vascular smooth muscle cell senescence through activating NF-κB-CTCF-p16 pathway
Presenter: xuefeng zheng
Session: Poster session 09
66P - Exploring the radiobiology and dosimetry of targeted alpha therapy as a tool to optimize its clinical application: A preclinical study
Presenter: Maria Filomena Botelho
Session: Poster session 09